Last updated: August 7, 2026
Roszet is a fixed-dose combination of rosuvastatin calcium and ezetimibe for patients requiring additional low-density lipoprotein cholesterol reduction. Its commercial value comes from combining two established mechanisms in one tablet, but the product also creates formulation challenges involving dose uniformity, dissolution, stability, tablet size, and manufacturing scale. The strongest excipient opportunities are in direct-compression platforms, low-moisture processing, taste and swallowability improvements, and differentiated dosage forms rather than in novel active ingredients.
What is Roszet and how is it formulated?
Roszet contains rosuvastatin calcium and ezetimibe in four strengths:
| Roszet strength |
Rosuvastatin calcium equivalent |
Ezetimibe |
| 5 mg/10 mg |
5 mg rosuvastatin |
10 mg |
| 10 mg/10 mg |
10 mg rosuvastatin |
10 mg |
| 20 mg/10 mg |
20 mg rosuvastatin |
10 mg |
| 40 mg/10 mg |
40 mg rosuvastatin |
10 mg |
The FDA approved Roszet in 2021 under NDA 214154. The product is indicated as an adjunct to diet for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, and for patients requiring additional LDL-C reduction. [1]
The product is an immediate-release, film-coated tablet. FDA labeling identifies inactive ingredients including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, magnesium stearate, titanium dioxide, and colorants that vary by strength. [1]
The formulation uses conventional excipients, but the combination is technically demanding because the two active ingredients have different physicochemical profiles. Ezetimibe has low aqueous solubility and depends heavily on particle size, wetting, and dispersion. Rosuvastatin calcium is administered at a much lower dose in some strengths and requires control of content uniformity. The formulation must deliver both actives consistently without compromising stability.
What excipient strategy best supports Roszet development?
A practical excipient strategy should separate the formulation functions of the two active ingredients while preserving a single-tablet manufacturing process.
Solubility and wetting
Ezetimibe is the primary solubility challenge. Sodium lauryl sulfate can improve wetting and dispersion, but its level must be controlled because excess surfactant can affect tablet hardness, dissolution profiles, gastrointestinal tolerability, and downstream regulatory comparability.
Potential commercial excipient options include:
- Sodium lauryl sulfate or other low-level surfactants for wetting.
- Poloxamers for improved dispersion and possible reduction of anionic surfactant load.
- Crospovidone or croscarmellose sodium for rapid liquid penetration.
- Spray-dried mannitol or co-processed excipients where fast disintegration and improved mouthfeel are priorities.
- Particle-engineered ezetimibe, including micronized or milled material, to reduce dependence on high surfactant levels.
The commercial opportunity is greatest where an excipient system improves dissolution without requiring a new chemical form of ezetimibe. A formulation that maintains equivalent exposure while using a simpler excipient profile could reduce manufacturing and regulatory risk.
Content uniformity
Rosuvastatin is present at 5 mg, 10 mg, 20 mg, or 40 mg, while ezetimibe remains fixed at 10 mg. The 5 mg/10 mg strength creates the highest relative content-uniformity burden because the rosuvastatin dose is small compared with the total tablet mass.
Suitable strategies include:
- Geometric dilution before final blending.
- Ordered mixing using carrier particles.
- Co-milled or co-processed active-excipient intermediates.
- Separate granulation of low-dose rosuvastatin before final blending.
- Roller compaction where moisture exposure must be minimized.
A supplier that offers a validated co-processed carrier for low-dose statin distribution could create value for generic and authorized-generic manufacturers. The relevant selling point is not the excipient identity alone. It is demonstrated blend uniformity, low segregation, scale-up performance, and compatibility with existing tablet presses.
Moisture and chemical stability
Rosuvastatin calcium formulations require control of moisture, temperature, and excipient impurities. Lactose-containing systems may require evaluation for reducing-sugar interactions, especially under elevated temperature and humidity. The risk profile depends on the active form, particle size, residual moisture, processing conditions, and packaging.
Commercially relevant approaches include:
- Low-moisture grades of microcrystalline cellulose.
- Anhydrous or low-water excipient systems.
- Moisture-barrier film coatings.
- Aluminum-aluminum blister packaging.
- High-density polyethylene bottles with desiccants.
- Antioxidant or chelator systems only when supported by compatibility data.
A low-moisture formulation can reduce dependence on aggressive packaging, but the tradeoff is often higher excipient cost or more demanding processing. For Roszet, packaging and excipient strategy should be developed together. A tablet that is stable only in high-barrier packaging may lose cost advantages at scale.
What formulations are protected by Roszet-related intellectual property?
Roszet-related protection can involve the fixed-dose combination, dosage strengths, manufacturing process, tablet composition, polymorphic form, and methods of reducing LDL cholesterol. The FDA Orange Book should be checked for current listed patents and regulatory exclusivity before relying on any launch or licensing analysis. [2]
Publicly available product information establishes the approved combination and strengths, but a commercial assessment should distinguish among three categories:
| Protection category |
Commercial relevance |
| Drug-substance patents |
May cover rosuvastatin calcium or ezetimibe forms, but much of the underlying protection is mature |
| Fixed-dose composition patents |
May cover the combination, ratios, excipients, or release characteristics |
| Method-of-use patents |
May affect labeling, indication carving, or Paragraph IV litigation |
Formulation patents are most valuable when they claim a narrow but commercially necessary feature, such as a defined dissolution profile, stability threshold, particle-size distribution, or excipient concentration range. Broad claims covering a tablet with rosuvastatin and ezetimibe may face validity and obviousness challenges because both actives are established products.
A generic manufacturer should evaluate whether it can design around the excipient system while maintaining bioequivalence. The ability to substitute croscarmellose sodium, crospovidone, different fillers, or alternative wetting agents may reduce formulation patent exposure.
When does Roszet lose exclusivity?
Roszet's commercial exclusivity depends on the applicable FDA regulatory exclusivity period, Orange Book-listed patents, pediatric exclusivity, and any litigation-related stay.
| Exclusivity issue |
Roszet assessment |
| FDA approval |
Approved in 2021 |
| Dosage form |
Immediate-release film-coated tablet |
| Generic pathway |
ANDA under section 505(j), subject to bioequivalence |
| Biosimilar pathway |
Not applicable because Roszet is a small-molecule drug |
| Paragraph IV risk |
Depends on current Orange Book patent listings |
| Pediatric exclusivity |
Must be confirmed from current FDA records |
| Patent expiry |
Must be confirmed patent-by-patent from the Orange Book and USPTO records |
Roszet does not face biosimilar competition. It faces conventional generic competition, authorized-generic competition, therapeutic substitution, and potential switching to separate rosuvastatin and ezetimibe tablets.
The key generic-launch scenarios are:
- A first ANDA applicant obtains approval after resolving or prevailing in Paragraph IV litigation.
- Multiple ANDA applicants enter after listed patents expire or are successfully challenged.
- A manufacturer launches separate-component products that compete with the combination without infringing Roszet formulation claims.
- A branded or authorized-generic supplier uses an existing manufacturing platform to compete on price.
Which companies are positioned to challenge Roszet?
Potential challengers include large generic manufacturers with established cardiovascular portfolios, vertically integrated active pharmaceutical ingredient suppliers, and contract manufacturers that already produce rosuvastatin and ezetimibe.
The most credible challengers are companies with:
- Existing rosuvastatin or ezetimibe ANDAs.
- Experience with low-dose blend uniformity.
- Validated immediate-release tablet facilities.
- Capacity for multiple strengths.
- Commercial access to wholesalers and pharmacy benefit managers.
- Regulatory infrastructure for Paragraph IV certifications.
The combination is commercially attractive because both active ingredients are familiar to generic manufacturers. The principal development barrier is unlikely to be discovery. It is formulation equivalence, patent clearance, and price positioning.
How large is the commercial opportunity for Roszet excipients?
Excipient suppliers can pursue four commercial models.
Premium formulation platforms
A supplier can offer a co-processed filler-disintegrant or solubility-enhancing system that reduces development time. The strongest value proposition is a platform tested with low-dose rosuvastatin and poorly soluble ezetimibe.
Generic development support
Generic manufacturers need excipient systems that support robust dissolution across strengths. A supplier that provides design-of-experiments data, compendial documentation, impurity profiles, and regulatory support can become embedded in the ANDA development program.
Manufacturing efficiency
Excipients that improve flow, reduce sticking, increase tablet tensile strength, or shorten blending time can lower production cost. These benefits matter because rosuvastatin and ezetimibe are low-cost active ingredients, making manufacturing efficiency central to margin protection.
Patient-centered dosage forms
Potential differentiated products include:
- Smaller tablets through higher-density excipients.
- Orally disintegrating tablets for patients with swallowing difficulty.
- Sprinkle formulations, if stability and dose uniformity can be demonstrated.
- Extended-release combinations, although these would require substantial clinical and regulatory development.
- Lower-pill-burden products combining lipid lowering with other cardiovascular medicines.
The most realistic near-term opportunity is a smaller, easier-to-swallow immediate-release tablet. An orally disintegrating Roszet product would require careful control of ezetimibe taste, rosuvastatin taste, friability, moisture sensitivity, and dose uniformity.
How strong is the Roszet patent estate?
The active ingredients have mature scientific and manufacturing knowledge, which limits the defensibility of broad composition claims. A narrower formulation patent may be stronger if it links a specific excipient range to an unexpected dissolution, stability, or bioavailability result.
Patent strength should be assessed against five factors:
- Claim breadth across excipient substitutions.
- Coverage of all four dosage strengths.
- Evidence of unexpected technical effects.
- Ability to prove infringement from publicly observable product characteristics.
- Availability of non-infringing formulation alternatives.
Method-of-use claims may have limited commercial impact if generic applicants use permitted labeling carve-outs. Composition and formulation claims are more relevant to actual tablet competition.
What litigation and settlement issues affect Roszet?
A complete litigation assessment requires current PACER, FDA, and Orange Book records. The main legal issues are likely to involve Paragraph IV certifications, obviousness of the fixed-dose combination, written description of formulation claims, and the scope of any method-of-use patents.
Settlement agreements in this area may include:
- Delayed generic entry.
- Authorized-generic supply rights.
- Licensed entry before patent expiry.
- Narrow labeling provisions.
- Restrictions on manufacturing or distribution channels.
Any settlement involving a first-filer should be reviewed for potential forfeiture of 180-day exclusivity and antitrust implications.
How does Roszet compare with separate rosuvastatin and ezetimibe products?
Roszet competes with both other fixed-dose combinations and separate tablets.
| Product strategy |
Advantages |
Commercial weakness |
| Roszet fixed-dose tablet |
One prescription and lower pill burden |
Less flexibility in titrating each active independently |
| Separate rosuvastatin plus ezetimibe |
Flexible dosing and broad generic availability |
Higher pill burden and possible adherence loss |
| Statin monotherapy |
Low cost and simple prescribing |
May not achieve LDL-C targets in high-risk patients |
| Other combination products |
Potential broader cardiovascular positioning |
May have different patent and reimbursement profiles |
Roszet's commercial position is strongest when clinicians want ezetimibe added to a stable rosuvastatin regimen and patients benefit from one tablet. Its position is weaker when dose titration, formulary substitution, or lowest-cost prescribing dominates.
Key Takeaways
- Roszet combines rosuvastatin calcium and ezetimibe in four immediate-release strengths.
- Ezetimibe creates the principal solubility and wetting challenge.
- The 5 mg/10 mg strength creates the highest low-dose content-uniformity burden.
- Lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and film-coating materials form the established excipient framework identified in FDA labeling.
- The strongest excipient opportunities are low-moisture systems, co-processed carriers, improved wetting systems, and smaller tablets.
- Roszet faces generic competition, not biosimilar competition.
- Patent value is likely to depend more on narrow formulation and method claims than on broad claims covering the known active ingredients.
- Generic entry timing depends on current Orange Book listings, Paragraph IV certifications, litigation, and settlement terms.
- Commercial upside exists for excipient suppliers that can document dissolution, stability, blend uniformity, and scale-up benefits.
FAQs
Can Roszet be reformulated without sodium lauryl sulfate?
Potentially. Alternative wetting agents, particle-size reduction, co-processing, or amorphous dispersion approaches may reduce or eliminate sodium lauryl sulfate, but the replacement must preserve dissolution, stability, bioequivalence, and tablet manufacturability.
Is Roszet suitable for an orally disintegrating tablet?
Potentially, but taste masking and moisture control would be major development requirements. Ezetimibe and rosuvastatin must remain uniformly distributed at low dose while the tablet disintegrates rapidly.
Does Roszet have biosimilar risk?
No. Roszet is a small-molecule combination product. Its principal competitive risk comes from ANDA-based generics and separate-component substitution.
Can a generic manufacturer use different excipients from Roszet?
Usually yes, provided the product meets applicable pharmaceutical equivalence and bioequivalence requirements and does not infringe valid formulation patents.
Which excipient is most commercially important for Roszet generics?
No single excipient determines success. The highest-value platform is likely a combined system that improves ezetimibe wetting, supports rosuvastatin content uniformity, limits moisture exposure, and maintains efficient tablet compression.
References
-
U.S. Food and Drug Administration. (2021). Roszet (rosuvastatin calcium and ezetimibe) tablets, prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.
-
U.S. Food and Drug Administration. (2018). ANDAs for certain highly soluble drug products and biowaiver considerations. FDA.
-
U.S. Food and Drug Administration. (2023). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. FDA.
